Page 39 - 2020_09-Haematologica-web

CLL pathogenesis and management
2015;1(1):80-87.
130.Flinn IW, Hillmen P, Montillo M, et al. The
phase 3 DUO trial: duvelisib vs ofatumum- ab in relapsed and refractory CLL/SLL. Blood. 2018;132(23):2446-2455.
131.Ghia P, Pluta A, Wach M, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamus- tine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020 May 27. [Epub ahead of print]
132.Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv 2019; 3(9):1553-1562.
133. Gribben JG. How and when I do allogeneic transplant in CLL. Blood. 2018;132(1):31-39. 134. Kharfan-Dabaja MA, Kumar A, Hamadani M, et al. Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the Guidelines Committee of the American Society for
Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2016;22(12): 2117-2125.
135.Dreger P, Ghia P, Schetelig J, et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood. 2018;132(9): 892-902.
136. Bair SM, Porter DL. Accelerating chimeric antigen receptor therapy in chronic lympho- cytic leukemia: the development and chal- lenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia. Am J Hematol. 2019;94(S1):S10-S17.
137.Sutton LA, Young E, Baliakas P, et al. Different spectra of recurrent gene muta- tions in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. Haematologica. 2016;101(8):959- 967.
138.Burger JA, Chiorazzi N. B cell receptor sig- naling in chronic lymphocytic leukemia. Trends Immunol. 2013;34(12):592-601.
139.Burger JA, Quiroga MP, Hartmann E, et al.
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood. 2009;113(13):3050-3058.
140.Dilillo DJ, Weinberg JB, Yoshizaki A, et al. Chronic lymphocytic leukemia and regula- tory B cells share IL-10 competence and immunosuppressive function. Leukemia. 2013;27(1):170-182.
141.LewinskyH,BarakAF,HuberV,etal.CD84 regulates PD-1/PD-L1 expression and func- tion in chronic lymphocytic leukemia. J Clin Invest. 2018;128(12):5479-5488.
142.De Matteis S, Molinari C, Abbati G, et al. Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lym- phocytic leukemia patients. J Transl Med. 2018;16(1):172.
143.Paggetti J, Haderk F, Seiffert M, et al. Exosomes released by chronic lymphocytic leukemia cells induce the transition of stro- mal cells into cancer-associated fibroblasts. Blood. 2015;126(9):1106-1117.
haematologica | 2020; 105(9)
2217